anti-PD-1xTL1A bispecific antibody

anti-PD-1xTL1A bispecific antibody is a novel dual-targeting bispecific antibody that co-targets programmed cell death protein 1 (PD-1) and tumor necrosis factor-like ligand 1A (TL1A). Developed by Nanjing Leads Biolabs, the antibody is generated by fusing novel PD-1 agonistic and TL1A antagonistic VHH domains in a tetra-valent format. It exerts synergistic immunomodulation through three complementary mechanisms: enhancing PD-1 inhibitory signaling, blocking the TL1A-DR3 pathway, and selectively depleting PD-1-expressing T cells via antibody-dependent cellular cytotoxicity (ADCC). Preclinical studies in mouse colitis models have demonstrated its potential to ameliorate disease activity, supporting its development for autoimmune diseases such as inflammatory bowel disease (IBD).

Other names

anti-PD-1 x TL1A bispecific antibodyanti-PD1 x TL1A bispecific antibodyanti-PD 1 x TL1A bispecific antibodyPD-1 x TL1A bispecific antibodyPD1 x TL1A bispecific antibodyPD 1 x TL1A bispecific antibodyPD-1/TL1A bispecific antibody